This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
TLDR Biotech
The top stories in biotech & pharma, straight to your inbox in only one email.Trusted by 3000+ biotech and pharma professionals.
I consent to receive newsletters via email. Terms of use and Privacy policy.
Comprehensive daily coverage of the biotech and pharma industry, straight to your inbox.
Aug 10, 2026
•
3 min read
🧬 Novo Nordisk, Amazon Web Services partner on AI drug discovery, launch London innovation hub, Silence Therapeutics' (divesiran) hits primary endpoint in Ph2 trial targeting TMPRSS6 for polycythemia vera, AbCellera's (ABCL635) Ph2 data surpass rivals in NK3R-targeting therapy for menopause-related hot flashes
Aug 8, 2026
6 min read
🧬 Human experience as a key driver in drug (re)discovery.
Aug 7, 2026
🧬 Replimune's Tudriqev (RP1) wins FDA accelerated approval for advanced melanoma post-PD-1 therapy failure, Tarsus Pharmaceuticals acquires Alkeus Pharmaceuticals for up to $800M to develop Stargardt disease treatment, Latigo Biotherapeutics raises $345.6M IPO to advance non-opioid pain drug pipeline
Aug 6, 2026
🧬 FDA approves Moderna's mFLUVISA, first mRNA-based flu vaccine, for seasonal influenza prevention in adults 50 and older, LifeMine Therapeutics raises $263M in venture financings, advancing novel organ transplant treatment, Schrödinger expands Bristol Myers Squibb partnership with large-scale Bunsen AI co-scientist deployment
Aug 5, 2026
🧬 Eli Lilly posts record $23B Q2 revenue, driven by Mounjaro and Zepbound despite slower Foundayo launch, Icon, Anthropic partner to deploy Claude AI into clinical trials via multi-year collaboration, Gilead Sciences' HIV prevention franchise surpasses $1B quarterly sales, raises full-year HIV growth guidance
Aug 4, 2026
🧬 Otsuka's Voyxact (sibeprenlimab) stabilizes kidney function decline to normal levels in Ph3 immunoglobulin A nephropathy trial, Pathos AI, AstraZeneca, Jiangsu Alphamab Biopharmaceuticals ink dual breast cancer deals, $125M upfront, $2.093B milestones, Merck & Co. raises 2026 sales guidance to $67.3B as Keytruda, Winrevair, and Lipfendra drive growth
Aug 3, 2026
🧬 Supernus Pharmaceuticals, Indivior Pharmaceuticals merge in all-stock deal, creating $2.2B CNS company with 11 approved drugs, Novartis' Pluvicto (lutetium vipivotide tetraxetan) wins FDA approval for PSMA-positive metastatic hormone-sensitive prostate cancer label expansion, AstraZeneca, Bristol Myers Squibb reportedly in early-stage merger talks valuing combined entity at $400B
Jul 31, 2026
🧬 Replimune's (vusolimogene oderparepvec) wins positive adcomm vote for advanced melanoma in Ph1/2 combination trial, AstraZeneca, Daiichi Sankyo's Datroway (datopotamab deruxtecan) gains EU approval for first-line unresectable or metastatic triple-negative breast cancer based on Ph3 data, Regeneron posts biggest quarterly revenue growth since pandemic on booming Dupixent sales
Jul 30, 2026
🧬 Johnson & Johnson pays Sail Biomedicines $785M upfront, option to acquire for $2.58B in in vivo CAR-T deal, Eli Lilly, Resilience commit $750M to boost US diabetes and obesity medicine production, Sanofi raises 2026 outlook after Dupixent quarterly sales surpass €5B ($5.73B) milestone